Protara Therapeutics, Inc. (TARA) is a clinical-stage biopharmaceutical company focused on therapies for cancer and rare diseases, not an ETF. Its lead asset, TARA-002, an investigational cell therapy, is in registrational trials for non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs), alongside an intravenous choline chloride program for patients on parenteral nutrition. With shares trading near $2.52 and analyst targets averaging around $25, the question of whether the stock can reach that level frames a debate between pipeline optimism and clinical-stage risk.
The $25 central target reflects roughly eight current analyst price targets, spanning a broad range from about $18 to $30. The arithmetic mean of these figures lands near $25.33, which rounds to a clean $25 objective. The wide dispersion is itself informative: bullish firms such as TD Cowen and Oppenheimer have carried targets as high as $28 to $30, while more cautious houses such as LifeSci Capital have trimmed targets toward $20 as the shares declined. In between sit Piper Sandler, H.C. Wainwright, and JonesTrading with Buy ratings in the $24 to $27 range, and J.P. Morgan and Cantor Fitzgerald maintain positive ratings without publicly current price targets.
The consensus leans strongly bullish—rated Strong Buy or Buy by essentially all covering analysts—but the range signals genuine uncertainty about how quickly and how completely TARA-002 can reach the market. Analysts cite the strong complete-response data in BCG-unresponsive NMIBC, the potential for a rolling BLA (Biologics License Application) submission in lymphatic malformations, and the company's manufacturing internalization as key drivers. No target here should be read as a guarantee; these are estimates, not forecasts of certainty.
With shares near $2.52 and a 52-week range of roughly $2.09 to $7.82, TARA trades far below its prior highs after a pronounced multi-month decline. Moving to $25 would require a gain of approximately 890%, which qualifies as a very large move by any standard. For context, the stock has already fallen more than 50% over the trailing year, leaving the analyst targets—many set when shares traded materially higher—well above the current price.
The path toward such a level would almost certainly need to run through clinical and regulatory milestones rather than gradual fundamental improvement, since the company generates no product revenue. Confirmation of TARA-002's efficacy in registrational cohorts, a completed rolling BLA submission, and eventual regulatory approval would be the kind of catalysts that have historically re-rated clinical-stage biotech names dramatically.
The core thesis rests on TARA-002. In February 2026 the company reported a 68% complete-response rate at six months in BCG-unresponsive NMIBC patients, a difficult-to-treat population, with no grade 3 or higher treatment-related adverse events. Management expects to complete enrollment of the BCG-unresponsive registrational cohort of the ADVANCED-2 trial by year-end 2026 and to complete STARBORN-1 enrollment in early 2027, setting up a rolling BLA submission in lymphatic malformations. A roughly $8.75 million acquisition of Novex Innovations' TARA-002 manufacturing assets also internalizes production capacity ahead of a potential launch. The balance sheet provides runway: about $143 million in cash and equivalents as of September 30, 2026, projected to fund operations into 2028.
The principal obstacle is binary clinical and regulatory risk. TARA-002's registrational data are not yet final, and later-stage results can underperform earlier readouts. The company is pre-revenue, with R&D (research and development) expenses rising as trials advance—third-quarter 2026 R&D spending grew to about $16.8 million from roughly $9.6 million a year earlier—and net losses widening. Any delay, redesign, or disappointing efficacy or safety signal could compress the valuation sharply, especially given a limited pipeline concentrated around a single product approach. Macroeconomic pressure on speculative, cash-burning biotech names also tends to weigh on sentiment regardless of company-specific progress.
The stock's long-term structure reflects a deep drawdown from the $7.82 52-week high to the $2.09 low, with the current price sitting near the lower portion of that range. The prior high near $7.82 stands as a distant resistance zone, while the $2.09 low and the $2.50 area represent nearby support. Because the analyst targets sit far above any recent trading level, the stock would need to reclaim multiple psychological and prior-resistance zones—well before approaching $25—before the technical picture could confirm a sustained trend change.
Analyst price targets generally reflect a research horizon of about 12 months, though individual firms may differ. The most consequential upcoming items are the interim results from the Phase 2b cohort of the THRIVE-3 trial of IV choline chloride, expected in the fourth quarter of 2026; completion of ADVANCED-2 enrollment by year-end; STARBORN-1 enrollment in early 2027; and progress toward a rolling BLA submission. Investors should also track cash burn, any additional financing, analyst target revisions, and updates on the redesigned ADVANCED-3 exploratory trial.
For traders seeking a more systematic view, Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals from changing market conditions, technical behavior, and AI-driven analysis. The tool is designed to help traders discover new opportunities, monitor existing positions, and spot shifting trends more efficiently than manual review allows. Because biotech names like TARA can move rapidly on news, an automated signal layer can help filter noise and highlight changes in trend. Traders interested in a data-driven edge may find the signals a useful complement to fundamental research.
Can Protara Therapeutics (TARA) reach $25? The target is not a guarantee but the arithmetic mean of current analyst price targets spanning roughly $18 to $30. Reaching it would demand an increase of about 890% from a price near $2.52—an exceptionally large move justified only if TARA-002 delivers on its registrational promise and reaches the market. The bulls point to encouraging efficacy data, a cash runway into 2028, and a slate of near-term readouts; the bears emphasize pre-revenue status, widening losses, and binary clinical risk. The next meaningful signposts—THRIVE-3 interim data, trial enrollment completions, and BLA progress—will determine whether the gap between the current price and the $25 objective narrows or widens.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, TARA has been loosely correlated with AMLX. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if TARA jumps, then AMLX could also see price increases.
| Ticker / NAME | Correlation To TARA | 1D Price Change % | ||
|---|---|---|---|---|
| TARA | 100% | +2.56% | ||
| AMLX - TARA | 40% Loosely correlated | -1.58% | ||
| ARVN - TARA | 40% Loosely correlated | -0.37% | ||
| OLMA - TARA | 39% Loosely correlated | +1.27% | ||
| ALT - TARA | 38% Loosely correlated | +1.44% | ||
| IMTX - TARA | 37% Loosely correlated | -2.46% | ||
More | ||||